Current Report Filing (8-k)
April 09 2020 - 4:03PM
Edgar (US Regulatory)
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
April 9, 2020
iBio, Inc.
(Exact name of registrant as specified in
its charter)
Delaware
(State or jurisdiction of incorporation
or organization)
001-35023
(Commission File Number)
26-2797813
(I.R.S. Employer Identification Number)
600 Madison Avenue, Suite 1601, New York,
NY 10022-1737
(Address of principal executive offices
(Zip Code)
Registrant's telephone number: (302) 355-0650
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
Emerging growth company
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Ticker symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock
|
|
IBIO
|
|
NYSE American
|
On
April 9, 2020, iBio, Inc. (“iBio”) issued a press release announcing the signing of two Master Services Agreements
(the MSAs”) and a Memorandum of Understanding (the “MoU”) with the Infectious Disease Research Institute (“IDRI”)
in support of iBio’s SARS-CoV-2 Virus-Like Particle (“VLP”) vaccine development. Under the MSAs, IDRI will support
pre-clinical development and provide clinical trial oversight, while iBio will provide process development and manufacturing services
to IDRI, as needed. Additionally, the MoU calls for iBio and IDRI to establish a separate, additional agreement within the next
60 days if iBio opts to include one of IDRI’s novel adjuvants in the COVID-19 vaccine development program (“IBIO-200”).
A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.
Signatures
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
IBIO INC.
|
|
|
|
|
|
|
|
Date: April 9, 2020
|
By:
|
/s/ Thomas F. Isett
|
|
|
|
Name:
|
Thomas F. Isett
|
|
|
|
Title:
|
Chief Executive Officer and
Executive Co-Chairman
|
|
iBio (AMEX:IBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
iBio (AMEX:IBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024